NCT00055861View on ClinicalTrials.gov

Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

August 31, 2006

Conditions
Recurrent Breast CancerStage IV Breast Cancer
Interventions
BIOLOGICAL

bevacizumab

Given IV

DRUG

docetaxel

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

43210

Ohio State University Medical Center, Columbus

80045

University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00055861 - Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter